Aclarion has been working over the last 18 months to build a consortium of leaders to test its Nociscan solution for distinguishing between painful and non-painful discs in the lumbar spine.
The company intends for each of the 10 leaders to begin using the technology, tracking clinical results and advocating for payer coverage to all Nociscan patients, according to a Nov. 6 press release.
As of right now, Dr. Hartl is the second leader to gain access to an MRI center authorized to perform Nociscans, making New York City and Denver the two active sites.
Chronic low back pain is a leading cause of opioid addiction in the U.S. Nociscan is the first platform that noninvasively helps physicians distinguish between painful and non-painful discs by quantifying chemical biomarkers that are associated with disc pain. The data is then entered into an algorithm to determine if a disc may be a source of pain.
The company plans to launch MRI activations for the remaining key opinion leaders in the coming months.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
